Fed. Circ. Revives Teva's Suit Over Aricept Patents
The U.S. Court of Appeals for the Federal Circuit said Wednesday that Teva’s suit against Eisai indeed presented an Article III controversy, and reversed and remanded a lower court ruling that had tossed the suit.
The appeals court said the delay Teva has experienced in obtaining regulatory approval...
To view the full article, register now.